[Treatment of cerebral circulatory insufficiency. Double-blind study of the efficacy of a quinine-papaverine combination].
Four weeks of oral therapy with a combination of quinine and papaverine at a dose of 3 X 1 coated tablet per day cause a marked and--as compared with placebo--statistically highly significant increase (p less than 0.01) in cerebral blood flow of patients with a moderate impairment of the terminal vascular system of the brain. The combination of substances brings about a more pronounced improvement (p less than 0.05) in the cerebral blood flow than papaverine alone which itself is superior to placebo (p less than 0.05). The quinine contained in the combination evidently increases its efficacy. The results of platelet aggregation tests, performed simultaneously, suggest that rheological factors in the sense of an improvement of the flow properties of the blood might play a part in causing these effects. Clinical and neurological findings indicate a clear parallel with the results of the measurements of the cerebral blood flow, even though this was not statistically significant.
D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D010208:Papaverine / Q000627:therapeutic use*; D010974:Platelet Aggregation; D011803:Quinine / Q000627:therapeutic use*; D013607:Tablets; D014980:Xenon Radioisotopes
D004338:Drug Combinations; D013607:Tablets; D014980:Xenon Radioisotopes; D011803:Quinine; D010208:Papaverine
Therapie der zerebralen Minderdurchblutung. Doppelblindstudie zur Wirkung einer Chinin-Papaverin-Kombination.